HF 22: CCM Therapy in Patients With HFpEF

Published: 22 May 2022

  • Views:

    Views Icon 229
  • Likes:

    Heart Icon 0

In this short interview, Dr Cecilia Linde (Karolinska University, SE) shares the findings of the CCM HFpEF Study. 
Originally presented at Heart Failure 22, this study aimed to evaluate the safety and efficacy of 
cardiac contractility modulation therapy in heart failure patients with preserved ejection fraction (HFpEF). 

Discussion Points:
1.  Study Background
2. Study Design & Patient Population
3. CCM Therapy
4. Key Findings
5. Patient Recommendations
6. Conclusions
7. Next Steps

Recorded on-site at Heart Failure 2022, Madrid.

Videographers: Tom Green and Mike Knight

Interviewer: Mirjam Boros